Earnings Preview: Legend Biotech
Portfolio Pulse from Benzinga Insights
Legend Biotech (NASDAQ:LEGN) is scheduled to release its quarterly earnings report on March 11, 2024, with an expected EPS of $-0.83. Historical data shows mixed reactions to past earnings, with the last quarter beating estimates but resulting in a 5.37% share price drop. Shares have risen 41.89% over the last year, indicating positive sentiment among long-term investors.
March 08, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Legend Biotech is expected to report an EPS of $-0.83 for the upcoming quarter. Historical performance shows mixed reactions to earnings announcements, with a notable share price drop following the last quarter's beat.
Given Legend Biotech's history of mixed stock price reactions to earnings reports, the upcoming announcement carries uncertainty. While the company beat last quarter's EPS estimates, the stock price fell, indicating that investor reactions can be unpredictable. The expected EPS of $-0.83 and the company's guidance will be key factors to watch. Positive guidance could boost investor sentiment, but the historical volatility post-earnings suggests a neutral short-term impact.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100